Cita APA

Salavert, M., Cobo, J., Pascual Hernández, Á., Aragón, B., Maratia, S., Jiang, Y., . . . Grau, S. (2018). Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.

Citación estilo Chicago

Salavert, Miguel|||0000-0002-8571-2124, Javier Cobo, Álvaro|||0000-0002-8672-5891 Pascual Hernández, Belén Aragón, Stefano Maratia, Yiling Jiang, Susana Aceituno, y Santiago|||0000-0002-8428-1836 Grau. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium Difficile Infection in High-Risk Patients in Spain. 2018.

Cita MLA

Salavert, Miguel|||0000-0002-8571-2124, et al. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium Difficile Infection in High-Risk Patients in Spain. 2018.